RT Journal Article
SR Electronic
T1 THE METABOLIC FATE OF PHENYLBUTAZONE (BUTAZOLIDIN) IN MAN
JF Journal of Pharmacology and Experimental Therapeutics
JO J Pharmacol Exp Ther
FD American Society for Pharmacology and Experimental Therapeutics
SP 481
OP 489
VO 113
IS 4
A1 J. J. BURNS
A1 ROSE K. ROSE
A1 SIDNEY GOODWIN
A1 JULES REICHENTHAL
A1 EVAN C. HORNING
A1 BERNARD B. BRODIE
YR 1955
UL http://jpet.aspetjournals.org/content/113/4/481.abstract
AB Two metabolic products of phenylbutazone have been isolated from the urine of subjects receiving the drug. One of them (Metabolite I), has been identified as a derivative of phenylbutazone in which one of the benzene rings is hydroxylated in the para position; the other (Metabolite II) as a derivative in which a hydroxyl group has been introduced in the 3 position of the butyl sidechain. Metabolite I is unusually stable in man having a biologic half-life of about two days, while Metabolite II has a half-life of about ten hours. After phenylbutazone administration Metabolite I apparently accumulates in the body in considerable amounts. The possible role of the metabolites of phenylbutazone in the overall antirheumatic or side-effects of the parent compound is discussed. © 1955, by The Williams & Wilkins Company